-
The British recovery will start here
Features There is a particular place where penny share expert Tom Bulford regularly finds great companies. He calls it the ‘new cradle of British industry’.
Features -
Why biotech is fast becoming the story of 2012
Features Professional investors are piling into biotech stocks - and hoping you won't notice, says Tom Bulford. So, don't miss out on what’s fast becoming the investment story of the year.
Features -
Things are looking up for this biotech
Tutorials When a company's shareholders are asked to pump more cash into the business, it's often bad news. But in the case of this small biotech firm, it could turn out to be a very profitable deal, says Bengt Saelensminde.
Tutorials -
The great technology story to replace the digital boom
Features Digital media was the great tech story of the last decade. But now there's a new tech story emerging, says Tom Bulford - and this one promises to be even more exciting.
Features -
Agreed bid for AGI Therapeutics
News Pharmaceutical company AGI Therapeutics is to be swallowed up by Aravis Therapeutics, a recently formed Irish subsidiary of Altiva.
News -
Glaxo to submit Relovair to regulatory authorities
News Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-a-day respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
News -
GlaxoSmithKline set to submit Relovair to regulators
News Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-daily respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
News -
Earnings at the lower end of forecasts, says AstraZeneca
News Biopharmaceutical giant AstraZeneca has said that full-year earnings are now expected to come in at the lower end of previous guidance.
News -
SkyePharma rocked by regulatory delay
News Drugs developer SkyePharma was sailing close to its 52-week low after it announced another regulatory delay for its asthma treatment, Flutiform.
News